Your browser doesn't support javascript.
loading
Cost-effectiveness of preimplantation genetic testing for aneuploidies.
Somigliana, Edgardo; Busnelli, Andrea; Paffoni, Alessio; Vigano, Paola; Riccaboni, Alessandra; Rubio, Carmen; Capalbo, Antonio.
Afiliação
  • Somigliana E; Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy; Obstetrics-Gynecology Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Electronic address: dadosomigliana@yahoo.it.
  • Busnelli A; Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
  • Paffoni A; ART Unit, Azienda Socio Sanitaria Territoriale Lariana, Come, Italy.
  • Vigano P; Obstetrics-Gynecology Department, San Raffaele Scientific Institute, Milan, Italy.
  • Riccaboni A; Obstetrics-Gynecology Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Rubio C; Igenomix, Molecular Genetics Laboratory, Valencia, Spain.
  • Capalbo A; Igenomix, Molecular Genetics Laboratory, Marostica, and La Sapienza Università di Roma, Rome, Italy.
Fertil Steril ; 111(6): 1169-1176, 2019 06.
Article em En | MEDLINE | ID: mdl-30777289
OBJECTIVE: To evaluate the economical benefit of preimplantation genetic testing of aneuploidies (PGT-A) when applied in an extended culture and stringent elective single ET framework. DESIGN: Theoretical cost-effectiveness study. SETTING: Not applicable. PATIENTS/ANIMAL(S): None. INTERVENTION(S): Comparison of the cost-effectiveness between two IVF treatment strategies: serial transfer of all available blastocysts without genetic testing (first fresh transfer and subsequent frozen-thawed transfer); and systematic use of genetic testing (trophectoderm biopsy, freeze-all, and frozen-thawed transfers of euploid blastocysts). The costs considered for this analysis are based on regional public health system provider. MAIN OUTCOME MEASURE(S): Costs per live birth. RESULT(S): Cost-effectiveness profile of PGT-A improves with female age and number of available blastocysts. Sensitivity analyses varying the costs of ET, the costs of genetic analyses, the magnitude of the detrimental impact of PGT-A on live birth rate, and the crude live birth rates change to some extent the thresholds for effectiveness but generally confirm the notion that PGT-A can be economically advantageous in some specific subgroups. CONCLUSION(S): PGT-A can be cost-effective in specific clinical settings and population groups. Economic considerations deserve attention in the debate regarding the clinical utility of PGT-A.
Assuntos
Palavras-chave

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Testes Genéticos / Custos de Cuidados de Saúde / Diagnóstico Pré-Implantação / Técnicas de Reprodução Assistida / Técnicas de Cultura Embrionária / Doenças Genéticas Inatas / Infertilidade / Aneuploidia Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Limite: Humans Idioma: En Revista: Fertil Steril Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Testes Genéticos / Custos de Cuidados de Saúde / Diagnóstico Pré-Implantação / Técnicas de Reprodução Assistida / Técnicas de Cultura Embrionária / Doenças Genéticas Inatas / Infertilidade / Aneuploidia Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Limite: Humans Idioma: En Revista: Fertil Steril Ano de publicação: 2019 Tipo de documento: Article